Guggenheim Maintains Buy on Tarsus Pharmaceuticals, Lowers Price Target to $89
Tarsus Pharmaceuticals, Inc.
Tarsus Pharmaceuticals, Inc. TARS | 0.00 |
Guggenheim analyst Brad Canino maintains Tarsus Pharmaceuticals (NASDAQ:
TARS) with a Buy and lowers the price target from $90 to $89.